发布时间：2008.6

摘要

Innovations in the Management of Diabetes: Next generation treatments and market dynamics’ is a new report published by Business Insights that analyzes the emerging drug classes, novel drug delivery technologies and future growth drivers of the diabetes market.


Additional Information

The management reports provide an in-depth and complete overview of each sector. By examining the topical issues and key market drivers, thes reports will equip you with the analysis and forecasting necessary to make the right decisions at the right time

目录及图表

Innovations in the Management of Diabetes

Executive Summary

Introduction

Currently marketed innovatives

Future drivers of growth and innovation

Key companies and pipelines

Future trends and implications

Chapter 1 Introduction

Summary

Introduction

Disease description

Type 1 diabetes

Type 2 diabetes

An increasing global health concern

Increasing patient population

Underdiagnosed and undertreated

Economic burden

Chapter 2 Currently marketed innovatives

Summary

Introduction

Current growth drivers

Insulins

Leading marketed innovatives within insulin

Exubera

Oral anti-diabetics (OADs)

Leading marketed innovatives in OADs

Other diabetic drugs

Leading marketed innovatives in other diabetic drugs

Chapter 3 Future drivers of growth and

innovation

Summary

Introduction

Unmet need

Key events in the global diabetes market

ACCORD trial halted 18 months early

Inhaled insulins fail to impact market

FDA considers stricter rules for diabetes drugs

Toward the prevention and further treatment of diabetes

Non-invasive forms of insulin via new drug delivery technologies

Inhaled insulins

Future potential of inhaled insulins

Oral insulins

Future potential of oral insulins

Insulin patches

Future potential of insulin patches

Emerging new drug classes: targeting underlying causes

Incretin mimetics: GLP-1 agonists and DDP-IV inhibitors

GLP-1 agonists in development

Novel GLP-1 agonists addressing unmet need

DDP-IV inhibitors in development

Novel DDP-IV inhibitors addressing unmet need

PPAR agonists

PPAR agonists in development

Novel PPAR agonists addressing unmet need

Sodium glucose co-transporter (SGLT) inhibitors

SGLT inhibitors in development

Cannabinoid-1 (CB1) receptor antagonists

CB-1 receptor antagonists in development

Glucokinase activators (GKA)

Glucokinase activators in development

Other novel drugs in development

Protein tyrosine phosphatase 1B (PT1B) inhibitors

Glycogen synthase kinase-3 (GSK-3) inhibitors

11-beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitors

GPR119 agonists

Cell transplantation and innovative therapies

Chapter 4 Key companies and pipelines

Summary

Introduction

Leading competitive strategies

Lifecycle management

Diversification

Franchise development

New market entry

Leading players

Novo Nordisk

Currently marketed innovatives profile

R&D/innovatives profile

Takeda

Currently marketed innovatives profile

R&D/innovatives profile

Sanofi-Aventis

Currently marketed innovatives profile

R&D/innovatives profile

GSK

Currently marketed innovatives profile

R&D/innovatives profile

Lilly

Currently marketed innovatives profile

R&D/innovatives profile

Merck.

Currently marketed innovatives profile

R&D/innovatives profile

Chapter 5 Future trends and implications

Summary

Introduction

Future market growth

Competitive strategy and future potential

Chapter 6 Appendix

IMS data

Index

List of Figures

Figure 3.1: Unmet needs in diabetes, 2008

Figure 3.2: Innovative diabetes pipeline, 2007

Figure 3.3: Addressing unmet need of novel GLP-1 agonists versus insulin

Figure 3.4: Addressing unmet need of novel DDP-IV inhibitors versus TZDs

Figure 3.5: Addressing unmet need of novel PPAR agonists* versus TZDs

Figure 4.6: Competitive dynamics of the leading players in the diabetes market, 2007

Figure 5.7: Drivers and resistors of growth in the innovative diabetes market, 2007

Figure 5.8: Forecast sales growth for the global diabetes market, 2007-12

Figure 5.9: Outlook for leading pharmaceutical companies in the innovative diabetes market

List of Tables

Table 2.1: Breakdown of the global diabetes market by drug class, 2003-07

Table 4.2: Leading diabetes companies*, 2006-07

Table 4.3: Novo Nordisk’s currently marketed innovative diabetes profile, 2003-07

Table 4.4: Novo Nordisk’s diabetes R&D/innovatives profile

Table 4.5: Takeda’s currently marketed innovative diabetes profile, 2003-07

Table 4.6: Takeda’s diabetes R&D/innovatives profile

Table 4.7: Sanofi-Aventis’ currently marketed innovative diabetes profile, 2003-07

Table 4.8: Sanofi-Aventis’ diabetes R&D/innovatives profile

Table 4.9: GSK’s currently marketed innovative diabetes profile, 2003-07

Table 4.10: GSK’s diabetes R&D/innovatives profile

Table 4.11: Lilly’s currently marketed diabetes innovative diabetes, 2003-07

Table 4.12: Lilly’s diabetes R&D/innovatives profile

Table 4.13: Merck’s currently marketed innovative diabetes profile, 2003-07

Table 4.14: Merck’s diabetes R&D/innovatives profile